{"id":"mk0733-simvastatin","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Myalgia (muscle pain)"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"2","effect":"Headache"},{"rate":"1-2","effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL1201391","moleculeType":"Small molecule","molecularWeight":"436.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Simvastatin is a statin that competitively inhibits HMG-CoA reductase, blocking the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This leads to decreased intracellular cholesterol production, upregulation of LDL receptors on hepatocytes, and enhanced clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:35.347Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT00652717","phase":"PHASE4","title":"Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-01","conditions":"Cardiovascular Disorder","enrollment":280},{"nctId":"NCT00551447","phase":"PHASE3","title":"A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-01","conditions":"Coronary Disease","enrollment":616},{"nctId":"NCT00092157","phase":"PHASE3","title":"Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-05-01","conditions":"Hypercholesterolemia","enrollment":571},{"nctId":"NCT00398294","phase":"PHASE4","title":"To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05-01","conditions":"Hypercholesterolemia","enrollment":30},{"nctId":"NCT00652301","phase":"PHASE3","title":"A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-07","conditions":"Cholesterol","enrollment":40},{"nctId":"NCT00389896","phase":"PHASE3","title":"A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-07-26","conditions":"HDL Cholesterol","enrollment":150},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00739050","phase":"PHASE4","title":"Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-09-19","conditions":"Systemic Lupus Erythematosus","enrollment":4},{"nctId":"NCT00652444","phase":"PHASE4","title":"Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09","conditions":"Hypercholesterolemia","enrollment":120},{"nctId":"NCT03885921","phase":"PHASE3","title":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-25","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00269217","phase":"PHASE3","title":"Lipid Efficacy Study (0524B-022)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":1400},{"nctId":"NCT00397826","phase":"PHASE4","title":"Evaluation of the Effects of Simvastatin 40mg","status":"COMPLETED","sponsor":"Cardinal Tien Hospital","startDate":"2005-01","conditions":"Hypercholesterolemia","enrollment":20},{"nctId":"NCT00738972","phase":"PHASE3","title":"Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)","status":"TERMINATED","sponsor":"Fundación Lindavista del Corazón AC","startDate":"2008-01","conditions":"Hypertension","enrollment":12},{"nctId":"NCT00753883","phase":"PHASE4","title":"Ezetrol Post-Marketing Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-07","conditions":"Hyperlipidemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0733, simvastatin","genericName":"MK0733, simvastatin","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}